Corona Remedies Ltd

Net profit of Corona Remedies declined 8.19% to Rs 41.27 crore in the quarter ended December 2025 as against Rs 44.95 crore during the previous quarter ended December 2024. Sales rose 15.03% to Rs 342.42 crore in the quarter ended December 2025 as against Rs 297.69 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales342.42297.69 15 OPM %24.2923.32 - PBDT83.7667.97 23 PBT74.3158.28 28 NP41.2744.95 -8 Powered by Capital Market - Live

Corona Remedies will hold a meeting of the Board of Directors of the Company on 2 February 2026.Powered by Capital Market - Live

Profit before tax (PBT) increased 21.67% year on year (YoY) to Rs 69.78 crore in Q2 FY26. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at Rs 78.47 crore, with EBITDA margin at 21.7% in Q2 FY26. Total expenditure climbed 14.4% YoY to Rs 282.66 crore. Raw material costs declined 9.3% YoY to Rs 25.9 crore. Employee expenses rose 17.3% YoY to Rs 103 crore. Interest costs eased 32.8% YoY to Rs 1.93 crore, while depreciation inched up 1.7% YoY to Rs 9.2 crore. On Half year basis, the company's consolidated net profit jumped 35.10% to Rs 98.52 crore on 16.92% jump in revenue from operations to Rs 707.67 crore in H1 FY26, compared with H1 FY25. Nirav K. Mehta, MD and CEO, CORONA Remedies, said: 'We are delighted to report a strong financial performance in Q2 and H1 FY26. Revenues for Q2 and H1FY26 grew by 15.1% and 17.0% respectively on a Y-o-Y basis, outperforming the IPM growth. Profit after tax for Q2 and H1FY26 grew by 21.8% and 35.1% respectively on a Y-o-Y basis while maintaining healthy return ratios. Our strong performance reflects the consistency of our strategy, disciplined execution and deep focus on our core therapeutic segments. By strengthening our field force, expanding our brand portfolio and maintaining a sharp focus on specialist's prescriptions, we have continued to outperform the market while building a sustainable platform for long-term growth. Lastly, we are grateful to our bankers for their efforts in the successful listing of CORONA on the Indian stock exchanges. I would also like to thank the entire team at CORONA and our stakeholders for their continued support and faith in our business.' Corona Remedies is an India-focused branded pharmaceutical formulation company developing, manufacturing, and marketing products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. Powered by Capital Market - Live

Profit before tax (PBT) increased 21.67% year on year (YoY) to Rs 69.78 crore in Q2 FY26. Total expenditure climbed 14.4% YoY to Rs 282.66 crore. Raw material costs declined 9.3% YoY to Rs 25.9 crore. Employee expenses rose 17.3% YoY to Rs 103 crore. Interest costs eased 32.8% YoY to Rs 1.93 crore, while depreciation inched up 1.7% YoY to Rs 9.2 crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at Rs 78.47 crore, with EBITDA margin at 21.7% in Q2 FY26. On Half year basis, the company's consolidated net profit jumped 35.10% to Rs 98.52 crore on 16.92% jump in revenue from operations to Rs 707.67 crore in H1 FY26, compared with H1 FY25. Nirav K. Mehta, MD and CEO, CORONA Remedies, said: 'We are delighted to report a strong financial performance in Q2 and H1 FY26. Revenues for Q2 and H1FY26 grew by 15.1% and 17.0% respectively on a Y-o-Y basis, outperforming the IPM growth. Profit after tax for Q2 and H1FY26 grew by 21.8% and 35.1% respectively on a Y-o-Y basis while maintaining healthy return ratios. Our strong performance reflects the consistency of our strategy, disciplined execution and deep focus on our core therapeutic segments. By strengthening our field force, expanding our brand portfolio and maintaining a sharp focus on specialist's prescriptions, we have continued to outperform the market while building a sustainable platform for long-term growth. Lastly, we are grateful to our bankers for their efforts in the successful listing of CORONA on the Indian stock exchanges. I would also like to thank the entire team at CORONA and our stakeholders for their continued support and faith in our business.' Corona Remedies is an India-focused branded pharmaceutical formulation company developing, manufacturing, and marketing products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. Shares of Corona Remedies rallied 3.05% to close at Rs 1,445.70 on the BSE on 2 January 2026.Powered by Capital Market - Live

Corona Remedies will hold a meeting of the Board of Directors of the Company on 2 January 2026.Powered by Capital Market - Live

The stock was listed at Rs 1,452, exhibiting a premium of 36.72% to the issue price. So far, the stock has hit a high of 1,499 and a low of 1,430.10. On the BSE, over 6.64 lakh shares of the company were traded in the counter so far. Corona Remedies was subscribed 137.04 times. The issue opened for bidding on 8 December 2025 and it closed on 10 December 2025. The price band of the IPO is fixed between Rs 1,008 and 1,062 per share. The IPO had been a complete offer for sale of equity shares, aggregating to Rs 655.37 crore, by existing shareholders Dr. Kirtikumar Laxmidas Mehta, Minaxi Kirtikumar Mehta, Dipabahen Niravkumar Mehta, Brinda Ankur Mehta, Sepia Investments, Anchor Partners, and Sage Investment Trust. The promoters and promoter group held an aggregate of 4,43,38,558 equity shares, aggregating to 72.5% of the pre-offer issued and paid-up equity share capital. Their post-IPO shareholding had been expected to be around 69%. Corona Remedies is an India-focused branded pharmaceutical formulation company developing, manufacturing, and marketing products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. It derives the majority of revenue, around 53.19% in Q1 FY26, from women's healthcare and cardio-diabeto therapeutic areas. As of June 30, 2025, the diverse portfolio included 71 brands across therapeutic areas such as women's healthcare, cardio-diabeto, pain management, urology, and others, as well as multispecialty pharmaceuticals comprising vitamins, minerals and nutrition (VMN), gastrointestinal, and respiratory segments. India accounted for 96.34% of the revenue in Q1 FY2026. Exports contributed 3.66%. It has a strong presence in the western zone of India, comprising Gujarat, Maharashtra, Goa, Madhya Pradesh, and Chhattisgarh. Ahead of the IPO of Corona Remedies on 5 December 2025, the company raised Rs 194.85 crore from anchor investors by allotting 18.34 lakh shares at Rs 1,062 each to 17 anchor investors. For the three months ended 30 September 2025, the firm recorded a consolidated net profit of Rs 46.20 crore and sales of Rs 346.54 crore.Powered by Capital Market - Live

The equity shares of Corona Remedies (Scrip Code: 544644) are listed effective 15 December 2025 and admitted to dealings on the Exchange in the list of ''B'' Group Securities. At 09:30 IST, the pre-open indicative price of the stock was at a premium of 4.61% to the issue price of Rs 1062. Powered by Capital Market - Live